迈得医疗(688310) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥51,996,527.67, representing a year-on-year increase of 10.93%[5] - The net profit attributable to shareholders decreased by 74.63% to ¥2,404,739.46 compared to the same period last year[5] - The net cash flow from operating activities was negative at -¥24,301,778.02, a decline of 253.51% year-on-year[5] - Total operating revenue for Q1 2022 was ¥51,996,527.67, an increase of 11.5% compared to ¥46,873,165.03 in Q1 2021[20] - Net profit for Q1 2022 was ¥2,205,325.56, a decrease of 76.5% from ¥9,354,043.72 in Q1 2021[21] - The company's gross profit margin decreased to 1.0% in Q1 2022 from 10.5% in Q1 2021[20] - The company reported a decrease in comprehensive income to ¥2,302,934.96 in Q1 2022, down from ¥9,545,941.81 in Q1 2021[21] Expenses and Investments - Research and development expenses totaled ¥8,748,981.09, an increase of 39.19% from the previous year, accounting for 16.83% of operating revenue, up by 3.42 percentage points[6] - The company reported a significant increase in management and R&D expenses, which outpaced revenue growth, leading to a substantial decline in net profit[8] - Research and development expenses increased to ¥8,748,981.09 in Q1 2022, compared to ¥6,285,834.86 in Q1 2021, marking an increase of 39.2%[20] - The company has invested CNY 10.41 million in Weigao Automation, acquiring 51% equity stake[12] Assets and Liabilities - The total assets at the end of the reporting period were ¥864,866,773.36, a decrease of 1.64% from the end of the previous year[6] - As of March 31, 2022, total assets amounted to CNY 864.87 million, a decrease from CNY 879.31 million as of December 31, 2021[17] - The total liabilities as of Q1 2022 were ¥95,630,201.56, a decrease from ¥116,670,640.13 in the previous year[18] - The total equity attributable to shareholders increased to ¥771,131,925.96 in Q1 2022 from ¥764,363,990.00 in Q1 2021[18] Cash Flow - Cash inflow from operating activities totaled $37,736,410.50, a decrease from $82,340,572.70 in the previous year, reflecting a decline of approximately 54.1%[24] - Net cash outflow from operating activities was $24,301,778.02, compared to a net inflow of $15,830,900.40 in the same period last year[24] - Cash inflow from investment activities amounted to $70,195,000.00, with a net cash outflow of $11,227,276.47, indicating a significant investment strategy[24] - Total cash outflow for purchasing fixed assets and other long-term assets was $26,422,276.47, up from $21,623,300.11 in the previous year[24] - Cash flow from financing activities resulted in a net outflow of $397,258.25, with no cash inflow recorded[25] - The ending balance of cash and cash equivalents was $278,858,739.67, down from $419,547,478.23 at the end of the previous year, reflecting a decrease of approximately 33.5%[25] - The company reported a significant increase in cash paid to employees, totaling $24,658,292.92, compared to $21,793,363.82 in the previous year, representing an increase of about 13.5%[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,476[10] - The largest shareholder, Lin Junhua, holds 39,986,000 shares, accounting for 47.83% of the total shares[10] Strategic Partnerships - The company has established a strategic partnership with Weigao Group, indicating a focus on market expansion in medical consumables[12] - The company has recognized Weigao Group as a related party due to the recent investment, impacting future transactions[14] Accounting Standards - The company is implementing new accounting standards starting in 2022, which may impact future financial reporting and analysis[25]